Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hospira’s Inflectra, EU’s First Biosimilar mAb, Will Challenge Skeptics

This article was originally published in The Pink Sheet Daily

Executive Summary

Hospira’s Inflectra becomes the first biosimilar monoclonal antibody to be authorized in Europe – but pricing and overcoming doctors’ skepticism looks like the key to real EU success.

Advertisement

Related Content

EU Demands Pfizer Offload Its Infliximab Biosimilar In Hospira Buy
Biosimilars Missing In Action: FDA, Sponsors Quiet About Pending Applications
J&J’s Gorsky Stands By Remicade Longevity As Biosimilar Impact Hits Europe
Korea’s Financial Regulator To Investigate Celltrion CEO On Alleged Insider Trading, Stock Manipulation
Korea’s Celltrion Will Support Hospira On EU Infliximab Sales While Setting Sights On Japan
Sandoz Biosimilar Strategy For Etanercept: Start Small, But Test Globally
Biosimilar Remicade Will Pit Rising Cost Pressures Against Prescriber Caution

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076220

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel